US2014128317A1PendingUtilityA1

Antiviral agent comprising recombinant mistletoe lectins

48
Assignee: LENTZEN HANSPriority: Feb 1, 2011Filed: Feb 1, 2012Published: May 8, 2014
Est. expiryFeb 1, 2031(~4.6 yrs left)· nominal 20-yr term from priority
A61P 31/12A61K 45/06A61K 38/168C07K 14/42Y02A50/30
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to an antiviral agent containing recombinant mistletoe lectins for treating virus infections and to a medicament and/or pharmaceutical composition for treating virus infections.

Claims

exact text as granted — not AI-modified
1 . An antiviral agent comprising recombinant mistletoe lectin for use with virus infections or so as to prevent virus infections, wherein the recombinant mistletoe lectin is selected from the group of the amino acid sequences SEQ ID Nos. 1-12, or comprises parts and fragments thereof, or a combination thereof. 
     
     
         2 . The antiviral agent according to  claim 1 , wherein the recombinant mistletoe lectin polypeptide is a mistletoe lectin A-chain, selected from the group of the amino acid sequences SEQ ID Nos. 1-3, or comprises parts and fragments thereof, or a combination thereof 
     
     
         3 . The antiviral agent according to  claim 1 , wherein the recombinant mistletoe lectin polypeptide is a mistletoe lectin B-chain, selected from the group of the amino acid sequences SEQ ID Nos. 4-12, or comprises parts and fragments thereof, or a combination thereof 
     
     
         4 . An antiviral agent according to  claim 1  for use with one of the following virus infections: Herpes simplex virus infection, adenovirus infection, poliovirus infection, poxvirus infection, parvovirus infection, papovavirus infection, hepadnavirus infection, orthomyxovirus infection, papilloma virus infection, paramyxovirus infection, coronavirus infection, picornavirus infection, reovirus infection, togavirus infection, flavivirus infection, arenavirus infection, rhabdovirus infection, and retrovirus infection. 
     
     
         5 . An antiviral agent according to  claim 1  for use with skin virus warts, anogential warts, mucous membrane warts and malignant tumors such as cervical cancer, penis and vulvar cancer. 
     
     
         6 . A medicinal drug comprising a recombinant mistletoe lectin polypeptide according to  claim 1 , optionally together with a pharmaceutically compatible carrier. 
     
     
         7 . A pharmaceutical composition comprising at least one recombinant mistletoe lectin polypeptide according to  claim 1 , together with a pharmaceutically compatible carrier, or optionally further adjuvants and additives. 
     
     
         8 . The pharmaceutical composition according to  claim 7  for treating one of the following virus infections: Herpes simplex virus infection, adenovirus infection, poliovirus infection, poxvirus infection, papilloma virus infection, parvovirus infection, papovavirus infection, hepadnavirus infection, orthomyxovirus infection, paramyxovirus infection, coronavirus infection, picornavirus infection, reovirus infection, togavirus infection, flavivirus infection, arenavirus infection, rhabdovirus infection, and retrovirus infection. 
     
     
         9 . The pharmaceutical composition according to  claim 7  for treating skin virus warts, anogential warts, mucous membrane warts and malignant tumors such as cervical cancer, penis and vulvar cancer. 
     
     
         10 . A pharmaceutical composition according to  claim 1 , wherein the composition is present in the form of a solution, gel or cream.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.